Clinical trial · Interventional
Characterization of Immunosuppressive Signing of Cervical Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Infection with Human Papillomavirus high-risk Human (HR-HPV) is the main factor of risk of cancer of the cervix. Recent studies show that cancers linked to infection with HR-HPV are associated with immunosuppression and lack of T cell response Such mechanisms would promote progression to cancer and progression of it . Various factors such as an increase of regulatory T cells, the presence of myeloid cells and suppressor of defects in the signaling pathway Toll Like Receptor (TLR) may have a key role in these immunosuppression mechanisms. At this stage of knowledge, a better characterization of local and systemic immunosuppressive signing of cervical cancer is needed. The results should have a significant medical impact for the identification of new prognostic markers and new therapeutic targets for the treatment of patients with cervical cancer. The aim of this research project is to define the signing of immunosuppressive cancer cervix and analyze the different mechanisms involved in this immunosuppression.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- patients with invasive cervical cancer
- description
- Blood sample
- interventionNames
- Biological: Blood sample
Primary outcomes (1)
- measure
- Lack of tumor emboli histological analysis
- timeFrame
- 60 months
- description
- Patients with good prognosis of cervical cancer
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * The women presenting for initial therapeutic management of cervical cancer * Elderly patients over 18 years * Patients beneficiary of a social security scheme * Pregnant women can not participate in this study * Women known to be HIV positive will not participate in this study Exclusion Criteria: * Patients with a recurrence of a treaty cervical cancer * Patients with a history of pelvic radiotherapy * Patients unable to receive informed about the progress and objectives of the study * Patients not receiving a social security scheme * Patients who have not signed informed consent * Immunocompromised patients and pregnant women
References
Publications (0)
Data not yet available